CN102784096A - Asiatic acid self-microemulsifying drug delivery system and its preparation method - Google Patents
Asiatic acid self-microemulsifying drug delivery system and its preparation method Download PDFInfo
- Publication number
- CN102784096A CN102784096A CN2011101293379A CN201110129337A CN102784096A CN 102784096 A CN102784096 A CN 102784096A CN 2011101293379 A CN2011101293379 A CN 2011101293379A CN 201110129337 A CN201110129337 A CN 201110129337A CN 102784096 A CN102784096 A CN 102784096A
- Authority
- CN
- China
- Prior art keywords
- asiatic acid
- delivery system
- medicament delivery
- self
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an asiatic acid self-microemulsifying drug delivery system (AA-SMEDDS) and its preparation method. The AA-SMEDDS comprises the following raw materials, by mass, 0.5-5% of AA, 10-50% of an oil phase, 30-75% of an emulsifier, and 0-30% of an emulsification assistant. The preparation method comprises the following steps: weighing a proper amount of the AA, adding formula amounts of the emulsification assistant and the emulsifier, stirring at 25-45DEG C to dissolve the AA, adding the oil phase and other auxiliary materials according to formula amounts, and uniformly stirring. An AA micro-emulsification oral preparation composition provided by the invention self-emulsifies to emulsion droplets with the particle sizes being below 100nm after the composition is orally taken and meets with a body fluid. The AA-SMEDDS has the advantages of simple preparation, good drug stability and high biological utilization degree.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, particularly a kind of asiatic acid self-micro emulsifying medicament delivery system and preparation method thereof.
Background technology
Herba Centellae is a Umbelliferae Centella plant, and (Asiatic acid AA) is the higher triterpene acids component of content wherein to asiatic acid, has pharmacologically active widely.Be mainly used in the treatment skin trauma in early days,, find that asiatic acid and derivant thereof have biological activitys such as antiinflammatory, antioxidation, antitumor, anti-hepatic fibrosis, pulmonary fibrosis resistant, cardiovascular protection along with to its bioactive further investigation.
The preparation asiaticoside sheet of present domestic listing, oral one time 2,3 times on the one.The research report is arranged, and asiaticoside changes into asiatic acid performance curative effect in vivo.Because the dissolubility of asiatic acid in water is minimum, does not have the preparation research about it at present.Infer that reason possibly be because the relatively poor oral administration biaavailability that causes of water solublity of asiatic acid is low, thereby be necessary to develop a kind of oral formulations of asiatic acid, to improve the oral administration biaavailability of asiatic acid.
Self-micro emulsifying medicament delivery system (Self-microemulsifying drug delivery system; SMEDDS) be meant the solution of the homogeneous that forms by oil phase, emulsifying agent and coemulsifier, transparent and drug; Under the condition of physiological condition or gentle agitation; Because the existence of emulsifying agent is met the water spontaneous emulsification and is formed particle diameter＜100nm oil-in-water emulsion, is called self-micro emulsifying medicament delivery system.The excellent carrier of the medicine that SMEDDS is an instability in slightly solubility, the water, oral administration biaavailability is low.Along with the successful appearance of ciclosporin soft capsule (Neoral), ritonavir soft capsule (Norvir) and Saquinavir soft capsule self-emulsifiable preparations such as (Fortovase), SMEDDS also receives much attention as the insoluble drug carrier in recent years.
SMEDDS has a lot of advantages as a kind of novel nano-lipid drug-supplying system.Because the self-microemulsion system is by oil phase, emulsifying agent and co-emulsifier are formed, and can improve the dissolubility of medicine greatly.Because self-microemulsion spontaneous emulsification in gastrointestinal tract becomes the very little emulsion droplet of particle diameter, have huge specific surface area simultaneously, can improve the dissolution rate of medicine.And with respect to traditional Emulsion, self microemulsifying preparation stability better.
Summary of the invention
The technical problem that the present invention will solve is exactly relatively poor to the asiatic acid water solublity; Bioavailability is low, lacks the defective of asiatic acid preparation at present, and a kind of asiatic acid self microemulsifying preparation and preparation method thereof is provided; Preparation technology is simple, and the bioavailability of asiatic acid improves greatly.
First aspect of the present invention provides a kind of asiatic acid self-micro emulsifying medicament delivery system, mainly includes asiatic acid and oil phase, emulsifying agent and the co-emulsifier of effect amount.Preferable comprises: 0.5%～5% asiatic acid, oil phase 10%-50%, emulsifying agent 30%-75% and co-emulsifier 0%-30%.Preferred described asiatic acid self-micro emulsifying medicament delivery system comprises: 1%-4% asiatic acid, oil phase 20%-50%, emulsifying agent 30%-60% and co-emulsifier 0%-25%.Percentage ratio is mass percent.
Among the present invention, described oil phase can be a natural plants oils, perhaps passes through the plant oil after structure of modification or the hydrolysis.Described oil phase can also be a fatty acid lipid.In preferable/certain herbaceous plants with big flowers acid triglyceride (GTCC) sad, isopropyl myristate (IPM), ethyl oleate, medium chain length fatty acid triglyceride (MCT), oleic acid polyethyleneglycol glyceride (Labrafil M 1944 CS), single glyceryl linoleate (Masine35-1) and the polypropylene glycol caprylate (Sefsol 218) of described oil phase one or more for being selected from.Preferred oil acid polyethylene glycol glyceride of the present invention (Labrafil M 1944 CS) is oil phase, its mass percent preferred 40%.
Among the present invention; Described emulsifying agent is the nonionic emulsifier of high HLB, and is preferable for being selected from polyoxyethylene castor oil (Cremophor EL), polyoxyethylene hydrogenated Oleum Ricini (Cremophor RH40), polyglycol distearate 15 (Solutol HS 15) and the sad capric acid polyethyleneglycol glyceride (Labrasol) one or more.The preferred polyoxyethylene castor oil of the present invention (Cremophor EL) is an emulsifying agent.Emulsifying agent has very strong emulsifying capacity, can spontaneous emulsification behind the contact body fluid, and emulsifying agent itself will have very big solvability to medicine, can prevent that medicine from precipitating to separate out in gastrointestinal tract.
Among the present invention, described co-emulsifier can be one or more in ethanol, ethylene glycol, Polyethylene Glycol, diethylene glycol list base ether, propylene carbonate and the propylene glycol.Preferable for being selected from dehydrated alcohol, PEG400 and the TC (Transcutol HP) one or more.The preferred TC of the present invention (Transcutol HP) is a co-emulsifier.The existing hydrophilic of described co-emulsifier has lipophile again, and co-emulsifier helps active component to form the solution and the stability that keeps solution of transparent and homogeneous.The adding of co-emulsifier not only can reduce interfacial tension, reduces the consumption of co-emulsifier, also can increase the dissolubility of medicine in preparation simultaneously.
Asiatic acid self-micro emulsifying medicament delivery system of the present invention can further include antioxidant etc.Antioxidant preferable like vitamin C and/or vitamin E, consumption is for being no more than 5%, percentage ratio is mass percent.
Second aspect present invention provides a kind of method for preparing of asiatic acid self-micro emulsifying medicament delivery system.Asiatic acid self-micro emulsifying medicament delivery system of the present invention can be according to the conventional method preparation of self-micro emulsifying medicament delivery system; Preferable method for preparing may further comprise the steps: take by weighing an amount of asiatic acid; The co-emulsifier and the emulsifying agent that add recipe quantity; Make medicine dissolution 25-45 ℃ of stirring, add oil phase and other adjuvants according to recipe quantity then, stirring promptly gets.
Asiatic acid self-micro emulsifying medicament delivery system of the present invention can be made into hard capsule, soft capsule, granule, tablet, dosage forms such as oral liquid.
Asiatic acid self-micro emulsifying medicament delivery system of the present invention can be used to prepare the medicine of antiinflammatory, antioxidation, antitumor, anti-hepatic fibrosis, pulmonary fibrosis resistant or cardiovascular protection, such as treatment wound, operation wound, burn, keloid or sclerodermatous medicine.
Raw material that the present invention is used or reagent except that specifying, all commercially available getting.
Than prior art; Beneficial effect of the present invention is following: the oral back of asiatic acid self-micro emulsifying medicament delivery system of the present invention is met the body fluid spontaneous emulsification and is become the emulsion droplet of particle diameter at 10～100nm in gastrointestinal tract; Significantly improve the dissolubility and the bioavailability of asiatic acid; Improve the clinical drug curative effect, for the exploitation of asiatic acid provides wide prospect.Asiatic acid self-micro emulsifying medicament delivery system preparation of the present invention is simple, and medicine stability is good.
Description of drawings
Below in conjunction with description of drawings characteristic of the present invention and beneficial effect.
Fig. 1 is an AA-SMEDDS dilution back particle size distribution.
Fig. 2 is an AA-SMEDDS transmission electron microscope photo (amplification: 20000).
Fig. 3 be rat oral gavage give behind AA-SMEDDS and the AA crude drug suspension average blood drug level-time graph in the body (ng/ml, n=5).
The specific embodiment
Further specify the present invention with embodiment below, but the present invention is not limited.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, or the condition of advising according to manufacturer.
Embodiment 1
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in the water-bath of 37 ℃ of degree, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Physicochemical property: adopt particle diameter and zeta potential after the Nicomp-380/ZLS laser granulometry is measured the dilution of asiatic acid self-microemulsion, particle size distribution is seen Fig. 1; Adopt NDJ-8S viscometer determining asiatic acid self-microemulsion viscosity.
The physicochemical property of table 1. asiatic acid self-microemulsion
Outward appearance:
Get the be preheated to 37 ℃ distilled water dilutings of AA-SMEDDS, shake up gently with 500 times of volumes, point sample, phosphotungstic acid negative staining, transmission electron microscope observing result show that AA-SMEDDS forms uniform oil-in-water type emulsion droplet after the water dilution.Transmission electron microscope scanning picture is seen Fig. 2.
The oral self-microemulsion drug-supplying system of asiatic acid pharmacokinetic characteristics:
Get 10 of SD male rats, be divided into 2 groups at random.First group of stomach of 12mg/Kg body weight filling according to dosage given the asiatic acid self-microemulsion, irritates stomach by identical dosage for second group and gives the asiatic acid suspension.After the administration in 0,5,15,30,60,120,240,360,480, the 720min posterior orbit gets blood, and is centrifugal under the 10000rpm/min, gets the determination of plasma drug level.With asiatic acid crude drug suspension as contrast.Blood drug level-time graph is seen Fig. 3, and main pharmacokinetic parameters is seen table 2, and the result shows the asiatic acid self-microemulsion, absorbs rapidly, has significantly improved the intravital bioavailability of rat.
The pharmacokinetic parameters (n=5) of table 2. rat oral gavage AA-SMEDDS and AA crude drug suspension
Embodiment 2
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Prescription is formed:
Asiatic acid 500mg
Oleic acid polyethyleneglycol glyceride (Labrafil M 1944CS) 3g
Polyoxyethylene castor oil (Cremophor EL) 7g
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Embodiment 4
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Embodiment 6
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Embodiment 7
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Embodiment 8
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation evenly gets final product.
Embodiment 9
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Embodiment 11
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Embodiment 12
Prescription is formed:
Preparation technology:
Take by weighing the medicine of recipe quantity, add the co-emulsifier and the emulsifying agent of recipe quantity, magnetic agitation evenly makes its dissolving in 37 ℃ of water-baths, adds oil phase and other adjuvants according to recipe quantity, and magnetic agitation is even.
Claims (7)
1. an asiatic acid self-micro emulsifying medicament delivery system is characterized in that, comprising: 0.5%～5% asiatic acid, and oil phase 10%-50%, emulsifying agent 30%-75% and co-emulsifier 0%-30%, percentage ratio are mass percent.
2. asiatic acid self-micro emulsifying medicament delivery system as claimed in claim 1 is characterized in that,
Described oil phase is to be selected from sad/certain herbaceous plants with big flowers acid triglyceride, isopropyl myristate, ethyl oleate, medium chain length fatty acid triglyceride, oleic acid polyethyleneglycol glyceride, single glyceryl linoleate and the polypropylene glycol caprylate one or more;
Described emulsifying agent is to be selected from polyoxyethylene castor oil, polyoxyethylene hydrogenated Oleum Ricini, polyglycol distearate 15 and the sad capric acid polyethyleneglycol glyceride one or more;
Described co-emulsifier is to be selected from ethanol, ethylene glycol, Polyethylene Glycol, diethylene glycol list base ether, propylene carbonate and the propylene glycol one or more.
3. according to claim 1 or claim 2 asiatic acid self-micro emulsifying medicament delivery system is characterized in that described asiatic acid self-micro emulsifying medicament delivery system also further comprises antioxidant.
4. asiatic acid self-micro emulsifying medicament delivery system as claimed in claim 3 is characterized in that, antioxidant is vitamin C and/or vitamin E, and consumption is for being no more than 5%, and percentage ratio is mass percent.
5. like each described asiatic acid self-micro emulsifying medicament delivery system of claim 1～4, it is characterized in that described asiatic acid self-micro emulsifying medicament delivery system is a hard capsule, soft capsule, granule, tablet or oral liquid formulation.
6. method for preparing like each described asiatic acid self-micro emulsifying medicament delivery system of claim 1～5; It is characterized in that; May further comprise the steps: take by weighing an amount of asiatic acid, add the co-emulsifier and the emulsifying agent of recipe quantity, make its dissolving 25～45 ℃ of stirrings; Add oil phase and other adjuvants according to recipe quantity then, stirring promptly gets.
7. like the application of each described asiatic acid self-micro emulsifying medicament delivery system of claim 1～5 in the medicine of preparation antiinflammatory, antioxidation, antitumor, fibrosis or cardiovascular protection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110129337.9A CN102784096B (en) | 2011-05-18 | 2011-05-18 | A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110129337.9A CN102784096B (en) | 2011-05-18 | 2011-05-18 | A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102784096A true CN102784096A (en) | 2012-11-21 |
| CN102784096B CN102784096B (en) | 2016-10-12 |
Family
ID=47149819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110129337.9A Active CN102784096B (en) | 2011-05-18 | 2011-05-18 | A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102784096B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878815A (en) * | 2016-06-24 | 2016-08-24 | 凌云 | Traditional Chinese medicinal self-microemulsion fast-release drop pill for treating coronary heart disease and preparation method |
| CN105943640A (en) * | 2016-06-24 | 2016-09-21 | 安徽高山药业有限公司 | Traditional Chinese medicine self-microemulsion instant release pill for treating myocardial ischemia and preparation method thereof |
| CN105943604A (en) * | 2016-06-24 | 2016-09-21 | 赵晶晶 | Self-microemulsion rapid-release compound Danshen dripping pill and preparation method |
| CN105943687A (en) * | 2016-06-24 | 2016-09-21 | 赵晶晶 | Traditional Chinese medicine self-microemulsion instant release pill for treating angina pectoris and preparation method thereof |
| CN106038930A (en) * | 2016-06-24 | 2016-10-26 | 凌云 | Traditional Chinese medicine fast release droppill for treating venomous snake bite and preparation method thereof |
| CN111840223A (en) * | 2019-04-22 | 2020-10-30 | 上海现代药物制剂工程研究中心有限公司 | Alisol A self-microemulsion composition and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004067012A1 (en) * | 2003-01-30 | 2004-08-12 | Shanghai Jahwa United Co., Ltd. | Limposomes containing asiaticoside and the uses thereof |
| CN1582946A (en) * | 2004-06-09 | 2005-02-23 | 崔福贵 | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels |
| WO2006019881A2 (en) * | 2004-07-14 | 2006-02-23 | Eldridge Gary R | Compositions and methods for controlling biofilms and bacterial infections |
| CN101474157A (en) * | 2009-01-19 | 2009-07-08 | 浙江省医学科学院 | Asiatic acid injectable sustained-release microballoons and preparation method thereof |
| CN101991532A (en) * | 2009-08-14 | 2011-03-30 | 上海开拓者医药发展有限公司 | Self-microemulsion composition, microemulsion and preparation methods thereof |
-
2011
- 2011-05-18 CN CN201110129337.9A patent/CN102784096B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004067012A1 (en) * | 2003-01-30 | 2004-08-12 | Shanghai Jahwa United Co., Ltd. | Limposomes containing asiaticoside and the uses thereof |
| CN1582946A (en) * | 2004-06-09 | 2005-02-23 | 崔福贵 | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels |
| WO2006019881A2 (en) * | 2004-07-14 | 2006-02-23 | Eldridge Gary R | Compositions and methods for controlling biofilms and bacterial infections |
| CN101474157A (en) * | 2009-01-19 | 2009-07-08 | 浙江省医学科学院 | Asiatic acid injectable sustained-release microballoons and preparation method thereof |
| CN101991532A (en) * | 2009-08-14 | 2011-03-30 | 上海开拓者医药发展有限公司 | Self-microemulsion composition, microemulsion and preparation methods thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杨蕊等: "齐墩果酸自微乳化给药系统的制备及其体外溶出度考察", 《中国药房》, vol. 21, no. 33, 31 December 2010 (2010-12-31) * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878815A (en) * | 2016-06-24 | 2016-08-24 | 凌云 | Traditional Chinese medicinal self-microemulsion fast-release drop pill for treating coronary heart disease and preparation method |
| CN105943640A (en) * | 2016-06-24 | 2016-09-21 | 安徽高山药业有限公司 | Traditional Chinese medicine self-microemulsion instant release pill for treating myocardial ischemia and preparation method thereof |
| CN105943604A (en) * | 2016-06-24 | 2016-09-21 | 赵晶晶 | Self-microemulsion rapid-release compound Danshen dripping pill and preparation method |
| CN105943687A (en) * | 2016-06-24 | 2016-09-21 | 赵晶晶 | Traditional Chinese medicine self-microemulsion instant release pill for treating angina pectoris and preparation method thereof |
| CN106038930A (en) * | 2016-06-24 | 2016-10-26 | 凌云 | Traditional Chinese medicine fast release droppill for treating venomous snake bite and preparation method thereof |
| CN111840223A (en) * | 2019-04-22 | 2020-10-30 | 上海现代药物制剂工程研究中心有限公司 | Alisol A self-microemulsion composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102784096B (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2257917C2 (en) | Self-emulsifying composition for scarcely water-soluble medicament | |
| TW546152B (en) | A storage-stable self-emulsifying preconcentrate of an anticancer drug such as taxane, pharmaceutical composition thereof and a method of enhancing the oral bioavailability of a taxane | |
| CN102784096B (en) | A kind of Asiatic acid self-microemulsifyindrug drug delivery system and preparation method thereof | |
| CN101862306B (en) | New type slightly soluble oral medicine self-emulsification preparation and preparation method thereof | |
| TW200422057A (en) | Composition in form of emulsion or microemulsion pre-concentrate for oral administration and its uses | |
| WO1996036316A1 (en) | Self-emulsifying formulations of lipophilic drugs | |
| CN113329736A (en) | Self-emulsifying oral preparation of terpene medicinal composition, preparation method and application | |
| CN101057829A (en) | Supersaturated cationic self-emulsified drug delivery system and its preparation method | |
| US6187747B1 (en) | Pharmaceutical composition comprising cyclosporin | |
| US9278065B2 (en) | Delivery systems for solubilising water-insoluble pharmaceutical active ingredients | |
| CN101780037B (en) | Dipyridamole self-emulsifying medicament administration system and preparation method thereof | |
| AU2007333355B2 (en) | Microemulsion dosage forms of valsartan and methods of making the same | |
| CN101390851A (en) | Double-cyclitol medicine composition containing surfactant and preparation method thereof | |
| CN101612121A (en) | The preparation of microemulsion containing paclitaxel method | |
| CN101103962A (en) | Vinpocetine oral self-micro-emulsification medicine-releasing system and preparation method thereof | |
| EP0982035B1 (en) | Cyclosporin composition comprising an hydrophilic carrier | |
| TWI599368B (en) | Capsule for oral administration comprising pharmaceutical composition alisporivir | |
| JP2942556B2 (en) | Novel composition containing cyclosporin | |
| EP1151755B1 (en) | Pharmaceutical compositions comprising cyclosporin as active ingredient | |
| US6346511B1 (en) | Pharmaceutical composition comprising cyclosporin | |
| CN102319302B (en) | Total paeony glucoside self-microemulsifying soft capsules and preparation method thereof | |
| CN101700224A (en) | Method for preparing oral chondroitin sulfate nanoemulsion | |
| KR101469953B1 (en) | Microemulsifying Drug Delivery System Composition Containing Foenumoside and Method for Preparing the Same | |
| CN1457795A (en) | Pueraria root flavone self-microemulsified soft capsule and its preparing method | |
| CN101011400A (en) | Piroxicam self-emulsifying pharmaceutical transmission system and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |